KYinno is a leading preclinical contract research organization (CRO) dedicated to providing tailored solutions in in vitro and in vivo pharmacology, cell line engineering, therapeutic target identification, and antibody discovery. Leveraging our proprietary assets, including over 3000 engineered cell lines, innovative bispecific and tri-specific antibody discovery mouse models, the comprehensive MPSA-AB5000 panel with screening capabilities for 5000 antibody specificities, and the cutting-edge KY-AITM antibody development artificial intelligence platform, we empower our clients to accelerate their research and development endeavors.

Located at F2 Building, Yizhuang Biomedical Park, No. 88, Kechuang Six Street, Beijing, P.R. China, 101111, and 204 Second Avenue, Waltham, MA 02451, USA, KYinno operates globally to serve the diverse needs of the biotechnology and pharmaceutical industries. Our team consists of highly skilled professionals committed to delivering exceptional results and exceeding expectations.

At KYinno, we are dedicated to advancing scientific discovery and therapeutic innovation. Learn more about how we can collaborate with you to achieve your research goals by visiting our website at www.kyinno.com.

KYinno – preclinical CRO – contract research organization – in vitro pharmacology – in vivo pharmacology – cell line engineering – therapeutic target identification – antibody discovery – engineered cell lines – bispecific antibodies – trispecific antibodies – antibody screening – antibody specificity screening – MPSA-AB5000 panel – KY-AITM antibody development platform – artificial intelligence platform